Tuesday, September 9, 2025 2:00 PM Eastern Time / 11:00 AM Pacific Time
Presenters:
James F. Howard, Jr., MD, FAAN – Professor of Neurology, Medicine & Allied Health
Director, Myasthenia Gravis Clinical Trials and Translational Research Program, The University of North Carolina at Chapel Hill
Thomas S. Grønnebæk, PhD – Principal Clinical Scientist at NMD Pharma A/S
Vera Kiyasova, MD, PhD – Clinical Development Director at NMD Pharma A/S
Join us to learn about new add-on, muscle-targeted therapy, a novel oral medication that is being developed by NMD Pharma for generalized myasthenia gravis. NMD Pharma’s clinical team, together with Dr. Howard, will explain how this molecule works and the science behind it, and will introduce the ongoing clinical trial and how you can join.
Register
After registering, you will receive a confirmation email containing information about joining the webinar.
This webinar is made possible by NMD Pharma.